# A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )

> **NCT01078558** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 5940 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01078558
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05-13
- **Primary completion:** 2018-01-11
- **Final completion:** 2018-01-11
- **Target enrollment:** 5940 (ACTUAL)
- **Last updated:** 2019-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01078558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01078558, "A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01078558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*